Despite the approval of targeted antibodies against key immune checkpoints, such as programmed death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) for various cancers, a significant subset of patients encounters resistance and treatment failure [204]. Here, CTLA4 is linked to cancer.